

LIDDS launches new website

Uppsala 15 March 2022 - LIDDS announced today that the company's new website, with updated content and design and improved functions, has been launched.

As part of ensuring good functionality and visualizing that LIDDS takes further steps in its development, the company has developed a new website. The website has updated content and a new graphic profile, which was also shown in the company's Year-end report and at the Capital Markets Day, which was held on 9 March. A link to the Capital Markets Day presentations and Q&A session can be found on the website, www.liddspharma.com.

For additional information, please contact

Nina Herne, CEO

Phone: +46 (0)70 714 74 57

E-mail: nina.herne@liddspharma.com

Jenni Björnulfson, CFO

Phone: +46 (0)708 55 38 05

E-mail: jenni.bjornulfson@liddspharma.com

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and solve problems within many indication areas. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage development, and projects about to enter clinical phase. The company is listed on Nasdaq First North Growth market.

Attachments

[LIDDS launches new website](#)